Shares of Be­yond­Spring sky­rock­et on new, pos­i­tive can­cer drug tri­al re­sults

Some­times re­sults come along that shock even a biotech’s be­liev­ers.

On Wednes­day, Be­yond­Spring, a small New York biotech with an off­beat ap­proach to im­munother­a­py, an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER